secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aditxt, Inc. (ADTX)
CIK:        0001726711
Form:       8-K
Filed at:   2026-06-01T12:30:22+00:00
Accession:  0001213900-26-063165
Event type: leadership
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aditxt names Jeffrey M. Busch Interim CEO; Amro Albanna steps down
------------------------------------------------------------------

- Amro Albanna resigned as CEO and director effective May 31, 2026; Rowena Albanna resigned as COO effective June 5, 2026.
- Jeffrey M. Busch appointed Interim CEO effective May 31, 2026; also continues as CEO of Ignite Proteomics subsidiary.
- Busch previously founded and led Global Medical REIT (NYSE: GMRE) to $1B enterprise value with ~8.5% avg dividend yield.
- Brian Brady appointed non-executive Chairman of the Board effective May 31, 2026.
- Shahrokh Shabahang resigned from Board but remains Chief Innovation Officer; departures not due to disagreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1726711/000121390026063165/0001213900-26-063165-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1726711/000121390026063165/ea0292902-8k_aditxt.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-063165

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer